GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » Price-to-Free-Cash-Flow

Aspira Womens Health (FRA:CUL) Price-to-Free-Cash-Flow : N/A (As of May. 25, 2024)


View and export this data going back to . Start your Free Trial

What is Aspira Womens Health Price-to-Free-Cash-Flow?

As of today (2024-05-25), Aspira Womens Health's share price is €2.02. Aspira Womens Health's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.35. Hence, Aspira Womens Health's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Aspira Womens Health's Price-to-Free-Cash-Flow or its related term are showing as below:

FRA:CUL's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 26.47
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Aspira Womens Health's Free Cash Flow per Share for the three months ended in Mar. 2024 was €-0.35. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-1.35.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 8.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -4.10% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 9.80% per year.

During the past 13 years, Aspira Womens Health's highest 3-Year average Free Cash Flow per Share Growth Rate was 56.70% per year. The lowest was -22.40% per year. And the median was 15.90% per year.


Aspira Womens Health Price-to-Free-Cash-Flow Historical Data

The historical data trend for Aspira Womens Health's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Price-to-Free-Cash-Flow Chart

Aspira Womens Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aspira Womens Health Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aspira Womens Health's Price-to-Free-Cash-Flow

For the Diagnostics & Research subindustry, Aspira Womens Health's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Price-to-Free-Cash-Flow falls into.



Aspira Womens Health Price-to-Free-Cash-Flow Calculation

Aspira Womens Health's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.02/-1.345
=N/A

Aspira Womens Health's Share Price of today is €2.02.
Aspira Womens Health's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Aspira Womens Health  (FRA:CUL) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Aspira Womens Health Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health (FRA:CUL) Business Description

Traded in Other Exchanges
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines